WEB GSK Wins Latest Zantac Trial
Jury Dismisses Claims Linking Drug to Cancer
WEB GSK has won its latest trial over whether its former best-selling drug caused cancer.
In a major victory for the pharmaceutical giant, a jury in Chicago on Monday ruled that Zantac, a popular heartburn medication, did not cause the plaintiff’s colon cancer.
The plaintiff, a woman in her 60s, alleged that she developed colon cancer after taking Zantac for several years. She claimed that the drug contained a chemical called ranitidine, which has been linked to cancer in some studies.
However, GSK’s attorneys argued that there was no scientific evidence to support the plaintiff’s claims. They also presented evidence that the plaintiff had other risk factors for colon cancer, such as a family history of the disease.
The jury agreed with GSK’s arguments and found that the plaintiff did not prove that Zantac caused her cancer. The verdict is a significant victory for GSK, which has been facing numerous lawsuits over Zantac.
In a statement, GSK said that it was “pleased” with the jury’s verdict. The company said that it “has always maintained that Zantac is safe and effective and that there is no credible scientific evidence to support the claims that it causes cancer.”
Comments